These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 27749600)
1. TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus. Shi B; Li J; Shi X; Jia W; Wen Y; Hu X; Zhuang F; Xi J; Zhang L J Acquir Immune Defic Syndr; 2017 Feb; 74(2):229-241. PubMed ID: 27749600 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection. Romito M; Juillerat A; Kok YL; Hildenbeutel M; Rhiel M; Andrieux G; Geiger J; Rudolph C; Mussolino C; Duclert A; Metzner KJ; Duchateau P; Cathomen T; Cornu TI Biotechnol J; 2021 Jan; 16(1):e2000023. PubMed ID: 33103367 [TBL] [Abstract][Full Text] [Related]
3. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Mock U; Machowicz R; Hauber I; Horn S; Abramowski P; Berdien B; Hauber J; Fehse B Nucleic Acids Res; 2015 Jun; 43(11):5560-71. PubMed ID: 25964300 [TBL] [Abstract][Full Text] [Related]
4. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1. Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection. Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597 [TBL] [Abstract][Full Text] [Related]
6. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype. Binninger-Schinzel D; Müller D; Wolf T; Krause B; Meye B; Winskowsky G; Raupp S; Norley S; Brodt R; Werner A J Med Virol; 2008 Feb; 80(2):192-200. PubMed ID: 18098144 [TBL] [Abstract][Full Text] [Related]
7. TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection. Yu AQ; Ding Y; Lu ZY; Hao YZ; Teng ZP; Yan SR; Li DS; Zeng Y Mol Med Rep; 2018 Jan; 17(1):243-249. PubMed ID: 29115572 [TBL] [Abstract][Full Text] [Related]
8. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. Hofer U; Henley JE; Exline CM; Mulhern O; Lopez E; Cannon PM J Infect Dis; 2013 Nov; 208 Suppl 2(Suppl 2):S160-4. PubMed ID: 24151324 [TBL] [Abstract][Full Text] [Related]
9. mRNA Transfection of T-Lymphocytes by Electroporation. Schwarze LI; Fehse B Methods Mol Biol; 2021; 2285():217-226. PubMed ID: 33928556 [TBL] [Abstract][Full Text] [Related]
10. TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Mussolino C; Alzubi J; Fine EJ; Morbitzer R; Cradick TJ; Lahaye T; Bao G; Cathomen T Nucleic Acids Res; 2014 Jun; 42(10):6762-73. PubMed ID: 24792154 [TBL] [Abstract][Full Text] [Related]
11. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967 [TBL] [Abstract][Full Text] [Related]
12. Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Ru R; Yao Y; Yu S; Yin B; Xu W; Zhao S; Qin L; Chen X Cell Regen; 2013; 2(1):5. PubMed ID: 25408877 [TBL] [Abstract][Full Text] [Related]
13. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4 Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D Cell Biosci; 2017; 7():47. PubMed ID: 28904745 [TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 4 (Tlr4) knockout rats produced by transcriptional activator-like effector nuclease (TALEN)-mediated gene inactivation. Ferguson C; McKay M; Harris RA; Homanics GE Alcohol; 2013 Dec; 47(8):595-9. PubMed ID: 24199847 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553 [TBL] [Abstract][Full Text] [Related]
16. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692 [TBL] [Abstract][Full Text] [Related]
17. Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Schwarze LI; Głów D; Sonntag T; Uhde A; Fehse B Gene Ther; 2021 Sep; 28(9):588-601. PubMed ID: 34112993 [TBL] [Abstract][Full Text] [Related]
18. Polyethylenimine-Mediated CCR5 Gene Knockout Using Transcription Activator-Like Effector Nucleases. Jin L; Deng Y; He N; Wang L; Weng M J Biomed Nanotechnol; 2018 Mar; 14(3):546-552. PubMed ID: 29663926 [TBL] [Abstract][Full Text] [Related]
19. Fully Automated One-Step Synthesis of Single-Transcript TALEN Pairs Using a Biological Foundry. Chao R; Liang J; Tasan I; Si T; Ju L; Zhao H ACS Synth Biol; 2017 Apr; 6(4):678-685. PubMed ID: 28103009 [TBL] [Abstract][Full Text] [Related]
20. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sather BD; Romano Ibarra GS; Sommer K; Curinga G; Hale M; Khan IF; Singh S; Song Y; Gwiazda K; Sahni J; Jarjour J; Astrakhan A; Wagner TA; Scharenberg AM; Rawlings DJ Sci Transl Med; 2015 Sep; 7(307):307ra156. PubMed ID: 26424571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]